Key Highlights

• Telix reported Q3 2026 group Revenue of US$245 million, up 19% year-over-year, with Precision Medicine revenue of US$201 million increasing 30%

• The U.S. FDA approved Pixclara for glioma imaging, marking the first approved imaging agent for this indication in the United States

• Telix reaffirmed FY 2026 revenue and other income is expected to exceed US$1 billion, tracking at the upper end of guidance

Telix Pharmaceuticals Ltd (ASX:TLX) closed at A$14.08 on 05 November 2026, advancing 5.71% on the session. The S&P/ASX 200 (XJO) gained 2.61%, or 230.60 points, to 9,065.10, while the S&P/ASX 200 Health Care index (XHJ) rose 3.64%, or 1,240.30 points, to 35,329.10. Overnight Wall Street gains, following the Democrats' decisive victory in the U.S. midterm elections, supported global Equity markets. Telix Pharmaceuticals is a radiopharmaceutical company focused on the development and commercialisation of diagnostic and therapeutic products targeting cancer and other diseases.

Q3 2026 Revenue Performance

On 21 October 2026, Telix released its Q3 2026 financial update for the quarter ended 30 September 2026. Group revenue reached US$245 million, a 19% increase over the prior corresponding quarter of US$206 million. Precision Medicine revenue contributed US$201 million of the total, up 30% year-over-year, driven by continued Demand for both Gozellix and Illuccix, the company's commercial PSMA-PET imaging products. Telix Manufacturing Solutions (TMS) third-party revenue came in at US$44 million, down 6% compared to Q3 2025.

CEO Dr Christian Behrenbruch noted that U.S. dose volumes increased 1% quarter-over-quarter, in line with expectations and reflecting typical summer seasonality. The September exit run rate was described as supporting confidence in delivering over 25% Precision Medicine revenue growth in 2026. Telix reaffirmed that FY 2026 revenue and other income is expected to exceed US$1 billion, with revenue tracking at the upper end of the US$950 million to US$970 million guidance range, plus US$40 million of other income.

FDA Approval and Pipeline Developments

During the quarter, the U.S. FDA approved Pixclara (floretyrosine F 18) for glioma imaging, establishing the first approved imaging agent for this indication in the United States. The first commercial doses were administered in September 2026. Additionally, the Phase 3 BiPASS study evaluating pre-biopsy prostate cancer detection completed enrolment of 350 patients, with the FDA supporting an NDA pathway and granting Fast Track Designation.

In the therapeutics pipeline, Part 2 of the ProstACT Global Phase 3 study for TLX591-Tx continues to enrol patients across seven countries outside the U.S. The OPTIMAL-PSMA Phase 2 study completed enrolment of 120 patients, with a data readout expected in the first half of 2027. Telix also announced a Merger with Isotope Technologies Munich SE (ITM), intended to create a vertically integrated radiopharmaceutical platform.

About Telix Pharmaceuticals

Telix is a radiopharmaceutical company listed on both the ASX and NASDAQ. The company's commercial portfolio includes PSMA-PET imaging products used in prostate cancer diagnosis, and it maintains a pipeline of therapeutic candidates across prostate cancer, kidney cancer, and brain cancer. The announced merger with ITM aims to combine Telix's commercial and clinical capabilities with ITM's isotope production and manufacturing infrastructure.

Sector Context

The ASX healthcare sector gained 3.64% on 05 November 2026. Within the radiopharmaceutical space, the growing adoption of PSMA-PET imaging in prostate cancer diagnosis and the expansion of therapeutic radiopharmaceuticals represent ongoing growth themes. Telix's position as a dual-listed entity on the ASX and Nasdaq provides it with access to both Australian and U.S. investor bases.

Risks

The radiopharmaceutical industry is subject to regulatory risk, as new product approvals and manufacturing licences require clearance from agencies including the FDA and the European Medicines Agency. The proposed merger with ITM introduces integration and execution risk. Revenue concentration in PSMA imaging products means that competitive entrants or shifts in prescribing preferences could affect growth. The revised R&D expenditure guidance of US$240 million to US$260 million for FY 2026 reflects the ongoing Investment requirements of a broad clinical pipeline.

Catalysts on Watch

Upcoming data readouts from the OPTIMAL-PSMA and ProstACT Global Phase 3 studies are key clinical catalysts. The commercialisation of Pixclara in the U.S. glioma imaging market will be watched for early uptake trends. Progress on the ITM merger, including regulatory approvals, represents a corporate catalyst. In Japan, NDA submission and potential market entry for Illuccix could open a new geographic revenue stream.

The Broader Outlook

Telix Pharmaceuticals' Q3 2026 results indicate continued revenue momentum in its Precision Medicine division, with group revenue approaching the upper end of FY26 guidance. The FDA approval of Pixclara and the advancement of multiple clinical programs reflect ongoing pipeline progression, while the proposed ITM merger could reshape the company's manufacturing and Supply chain capabilities.